MaxCyte (NASDAQ:MXCT) Releases Earnings Results, Beats Expectations By $0.06 EPS

MaxCyte (NASDAQ:MXCT) announced its quarterly earnings data on Tuesday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.06, FiscalAI reports. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 19.67%. The firm had revenue of $6.22 million during the quarter, compared to analyst estimates of $7.28 million.

Here are the key takeaways from MaxCyte’s conference call:

• MaxCyte reported Q1 revenue of $9.7 million, which met management’s expectations, and reiterated full-year 2026 guidance of $30 million-$32 million in total revenue.
• Core revenue fell 25% year over year to $6.2 million, pressured by inventory management at its largest SPL customer and the impact of discontinued SPL programs.
• The company highlighted improving momentum in its SPL pipeline, with 29 partners and expectations for at least three new SPL signings in 2026, plus multiple later-stage programs advancing toward registrational trials.
• New products are starting to contribute: ExPERT DTx is seeing encouraging early adoption, while SeQure posted $0.6 million in Q1 revenue and management said the recent FDA draft guidance should be a structural positive for the business.
• MaxCyte is benefiting from a much leaner cost structure, with Q1 operating expenses down to $14.3 million from $21.2 million a year ago, $147.7 million in cash and investments, and a newly authorized $10 million share repurchase program.

MaxCyte Stock Up 7.4%

Shares of MaxCyte stock traded up $0.08 on Thursday, hitting $1.10. The company’s stock had a trading volume of 1,610,596 shares, compared to its average volume of 1,057,036. The company has a market capitalization of $117.30 million, a P/E ratio of -2.94 and a beta of 1.37. The firm has a fifty day moving average price of $0.80 and a 200-day moving average price of $1.14. MaxCyte has a 52-week low of $0.64 and a 52-week high of $2.40.

Analyst Ratings Changes

A number of research firms have weighed in on MXCT. Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a report on Friday, April 24th. Craig Hallum decreased their target price on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, March 25th. Finally, Wall Street Zen lowered shares of MaxCyte from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $5.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. purchased a new position in MaxCyte in the 2nd quarter valued at about $26,000. State of Wyoming acquired a new position in shares of MaxCyte during the 2nd quarter valued at about $38,000. Jain Global LLC acquired a new position in shares of MaxCyte during the 4th quarter valued at about $45,000. BNP Paribas Financial Markets increased its stake in shares of MaxCyte by 266.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after acquiring an additional 18,913 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of MaxCyte during the 4th quarter valued at about $67,000. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical?stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical?scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.